Clinical effect of intraoperative electron beam radiotherapy in treatment of unresectable locally advanced pancreatic cancer
Zheng Miaoli, Song Yongwen, Feng Qinfu, Chen Yingtai, Zhai Yirui, Li Minghui, Fang Hui, Zhang Jianwei, Ma Pan, Wang Chengfeng
Department of Radiation Oncology (Zheng ML,Song YW,Feng QF,Zhai YR,Li MH,Fang H,Ma P),Department of Abdomina Surgery (Chen YT,Zhang JW,Wang CF),National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China
Abstract：Objective To assess the prognostic benefits of intraoperative radiotherapy (IORT) with electron beam among patients with unresectable locally advanced pancreatic cancer. Methods Between January 2009 and December 2014, 167 patients with unresectable locally advanced pancreatic cancer received IORT with electron beam (10-20 Gy) in our hospital. After surgery, 12 patients were treated with external beam radiotherapy, 56 patients with chemoradiotherapy (CRT), and 17 patients with chemotherapy. Overall survival (OS), local recurrence, and toxicities were retrospectively analyzed. The Kaplan-Meier method was used to calculate survival rates, the log-rank test was used for survival difference analysis andunivariate prognostic analysis, and the Cox model was used for multivariate prognostic analysis. Results The follow-up rate was 100%. The median OS time was 10.3 months, and the 2-year OS rate was 22%. The median progression-free survival (PFS) time was 6.3 months, and the 2-year PFS rate was 9.9%. The cancer-specific survival (CSS) time was 11.2 months, and the 2-year CSS rate was 23.6%. In the patients treated with IORT alone at doses of<15 Gy, 15 Gy and>15 Gy, the median OS times were 6.2 months vs. 9.1 months vs. 22.2 months, and the 1-year OS rates were 10.0% vs. 39.6% vs. 74.4%(P=0.000). Among the patients receiving postoperative adjuvant therapy, those treated with IORT+CRT had the best survival, with a median OS time of 11.6 months (P=0.033). The univariate analysis showed that IORT dose (P=0.000), tumor size (P=0.006), and IORT applicator diameter (P=0.007) were prognostic factors. The multivariate analysis showed that IORT dose (P=0.000) and IORT combined with CRT (P=0.006) were independent prognostic factors. Conclusions IORT with electron beam is an effective and safe treatment strategy for unresectable locally advanced pancreatic cancer. After protecting surrounding organs, increasing the IORT dose can improve the survival. IORT combined with CRT should be recommended because it improves survival for unresectable locally advanced pancreatic cancer without increasing toxicities.
Zheng Miaoli,Song Yongwen,Feng Qinfu et al. Clinical effect of intraoperative electron beam radiotherapy in treatment of unresectable locally advanced pancreatic cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(4): 405-409.
[1] Gudjonsson B.Cancer of the pancreas.50 years of surgery[J].Cancer,1987,60(9):2284-2303 [2] Jemal A,Siegel R,Ward E,et al. Cancer statistics[J],2008,CA Cancer J Clin,2008,58(2):71-96.DOI:10.3322/CA.2007.0010 [3] Treatment of Locally Unresectable Carcinoma of the Pancreas:Comparison of Combined-Modality Therapy (Chemotheraphy Plus Radiotherapy) to Chemotheraphy Alone. Gastrointestinal Tumor Study Group[J].J Natl Cancer Inst,1988,80(10):751-755 [4] Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group[J].Cancer,1985,56(11):2563-2568 [5] Burris HA 3rd,Moore MJ,Andersen J,et al. Improvments in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403-2413.DOI:10.1200/JCO.1997.15.6.2403 [6] Louvet C,Labianca R,Hammel P,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:results of a GERCOR and GISCAD phase Ⅲ trial[J].J Clin Oncol,2005,23(15):3509-3516.DOI:10.1200/JCO.2005.06.023 [7] Willett CG,Czito BG,Bendell JC,et al. Locally advanced pancreatic cancer[J].J Clin Oncol,2005,23(20):4538-4544.DOI:10.1200/JCO.2005.23.911 [8] Calvo FA,Meirino RM,Orecchia R.Intraoperative radiation therapy part 2.Clinical results[J].Crit Rev Oncol Hematol,2006,59(2):116-127.DOI:10.1016/j.critrevonc.2006.04.004 [9] Ruano-Ravina A,Almazán Ortega R,Guedea F.Intraoperative radiotherapy in pancreatic cancer:a systematic review[J].Radiother Oncol,2008,87(3):318-325.DOI:10.1016/j.radonc.2007.12.002. [10] Nagai S,Fujii T,Kodera Y,et al. Prognostic Implications of Intraoperative Radiotherapy for Unresectable Pancreatic Cancer[J].Pancreatology,2011,11(1):68-75.DOI:10.1159/000324682. [11] Sindelar WF,Kinsella TJ.Studies of intraoperative radiotherapy in carcinoma of the pancreas[J].Ann Oncol,1999,10 Suppl 4:226-230. [12] Valentini V,Calvo F,Reni M,et al. Intra-operative radiotherapy (IORT) in pancreatic cancer:joint analysis of the ISIORT-Europe experience[J].Radiother Oncol,2009,91(1):54-59.DOI:10.1016/j.radonc.2008.07.020. [13] Jingu K,Tanabe T,Nemoto K,et al. Intraoperative radiotherapy for pancreatic cancer:30-year experience in a single institution in Japan[J].Int J Radiat Oncol Biol Phys,2012,83(4):e507-e511.DOI:10.1016/j.ijrobp.2012.01.024. [14] Ishikawa H,Suzuki Y,Nakayama Y,et al. Intraoperative radiotherapy and bypass surgery for unresectable pancreatic cancer[J].Hepatogastroenterology,2000,47(34):1151-1155. [15] Mohiuddin M,Regine WF,Stevens J,et al. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas[J].J Clin Oncol,1995,13(11):2764-2768.DOI:10.1200/JCO.1995.13.11.2764. [16] Okamoto A,Tsuruta K,Karasawa K,et al. Resection versus palliation:treatment of stage Ⅲ and ⅣA carcinomas of the pancreas employing intraoperative radiation[J].World J Surg,2003,27(5):599-605.DOI:10.1007/s00268-003-6579-6. [17] Ogawa K,Karasawa K,Ito Y,et al. Intraoperative radiotherapy for unresectable pancreatic cancer:a multi-institutional retrospective analysis of 144 patients[J].Int J Radiat Oncol Biol Phys,2011,80(1):111-118.DOI:10.1016/j.ijrobp.2010.01.065. [18] 张建伟,车旭,陈应泰,等.局部进展期胰腺癌术中放疗后的早期并发症[J].中华肿瘤杂志,2014,36(6):473-475.DOI:10.3760/cma.j.issn.0253-3766.2014.06.017. Zhang JW,Che X,Chen YT,et al. Early complications of intra-operative radiotherapy in locally advanced pancreatic cancer[J].Chin J Oncol,2014,36(6):473-475.DOI:10.3760/cma.j.issn.0253-3766.2014.06.017. [19] Abe M,Shibamoto Y,Takahashi M,et al. Intraoperative radiotherapy in carcinoma of the stomach and pancreas[J].World J Surg,1987,11(4):459-464. [20] Kawamura M,Kataoka M,Fujii T,et al. Electron beam intraoperative radiation therapy (EBIORT) for localized pancreatic carcinoma[J].Int J Radiat Oncol Biol Phys,1992,23(4):751-757. [21] Moertel CG,Frytak S,Hahn RG,et al. Therapy of locally unresectable pancreatic carcinoma:a randomized comparison of high dose (6000 rads) radiation alone,moderate dose radiation (4000 rads+5-fluorouracil),and high dose radiation+5-fluorouracil. The gastrointestinal tumor study group[J].Cancer,1981,48(8):1705-1710. [22] Sultana A,Tudur Smith C,Cunningham D,et al. Systematic review,including meta-analyses,on the management of locally advanced pancreatic cancer using radiation/combined modality therapy[J].Br J Cancer,2007,96(8):1183-1190.DOI:10.1038/sj.bjc.6603719 [23] Cai S,Hong TS,Goldberg SI,et al. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital,1978 to 2010[J].Cancer,2013,119(23):4196-4204.DOI:10.1002/cncr.28329.
2017, Vol. 26 
